

CITATION REPORT

List of articles citing

Clinical pharmacokinetics of cyclophosphamide

DOI: 10.2165/00003088-200544110-00003
Clinical Pharmacokinetics, 2005, 44, 1135-64.

Source: <https://exaly.com/paper-pdf/39421326/citation-report.pdf>

Version: 2024-04-18

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
290	High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. 2006 , 94, 1226-30		53
289	The safety profile of cyclophosphamide in multiple sclerosis therapy. 2007 , 6, 183-90		51
288	Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. 2007 , 320, 72-80		251
287	A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. 2007 , 67, 10159-62		140
286	Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 760-4	4.7	25
285	Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: pharmacokinetics, liver toxicity, and mortality. <i>Biology of Blood and Marrow Transplantation</i> , 2007 , 13, 853-62	4.7	75
284	Cancer chemotherapy II: atypical hepatic injuries. 2007 , 11, 663-76, viii		11
283	Population pharmacokinetics of the BEACOPP polychemotherapy regimen in Hodgkin's lymphoma and its effect on myelotoxicity. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 319-33	6.2	14
282	Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 1051-68	6.2	34
281	Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS). <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 854, 345-9	3.2	35
280	Systemic anticancer therapy in gynecological cancer patients with renal dysfunction. 2007 , 17, 739-63		38
279	Effect of lower dose intravenous cyclophosphamide on remission induction in Korean patients with lupus nephritis. 2008 , 28, 453-8		4
278	Protective effect of zinc on cyclophosphamide-induced hematotoxicity and urotoxicity. 2008 , 126, 186-93		17
277	The effect of administration order of BU and CY on engraftment and toxicity in HSCT mouse model. <i>Bone Marrow Transplantation</i> , 2008 , 41, 895-904	4.4	22
276	Serious haematological toxicity of cyclophosphamide in relation to CYP2B6, GSTA1 and GSTP1 polymorphisms. 2008 , 65, 279-80		15
275	Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction. 2008 , 44, 162-73		53
274	Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients. 2008 , 106, 217-26		72

273	Predicting and preventing the cardiotoxicity of cancer therapy. 2008 , 6, 1023-33		8
272	New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. 2008 , 100, 1058-67		128
271	Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. 2008 , 16, 1665-73		100
270	CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. 2008 , 9, 598-610		240
269	Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. 2008 , 18, 515-23		93
268	Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. 2008 , 18, 1009-15		34
267	Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis. 2009 , 49, 965-72		6
266	Population pharmacokinetics of cyclophosphamide and metabolites in children with neuroblastoma: a report from the Children's Oncology Group. 2009 , 49, 88-102		32
265	Fulminant polyarteritis nodosa associated with acute myeloid leukaemia resulted in bilateral lower leg amputation. 2009 , 48, 1170-2		4
264	Clearing the MIST (metabolites in safety testing) of time: The impact of duration of administration on drug metabolite toxicity. 2009 , 179, 60-7		27
263	Arsenate and dimethylarsinic acid in drinking water did not affect DNA damage repair in urinary bladder transitional cells or micronuclei in bone marrow. 2009 , 50, 760-70		11
262	Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 375-9	3.5	11
261	Carbamazepine induces bioactivation of cyclophosphamide and thiotepa. <i>Cancer Chemotherapy and Pharmacology</i> , 2009 , 63, 543-7	3.5	14
260	Determination of Chloride 3-Methyl-9-(2-oxa-2 β -2H-1,3,2-oxazaphosphorine-2-cyclohexyl)-3,6,9-triazaspiro [5.5] undecane (SLXM-2) in Rats by LC: Application to a Pharmacokinetic Study. 2009 , 69, 111-115		1
259	An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. 2009 , 35, 18-31		67
258	Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy. 2009 , 10, 1897-903		62
257	Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients. 2009 , 54, 564-71		46
256	Alpha-tocopherol and ginger are protective on Cyclophosphamide-induced gonadal toxicity in adult male albino rats. 2009 , 2, 21-29		3

255	Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen. 2009 , 31, 95-103	3
254	Pharmacogenomics. 2009 ,	
253	Review article: systemic lupus erythematosus: a review for anesthesiologists. 2010 , 111, 665-76	35
252	Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management. 2010 , 3, 129-43	6
251	Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. 2010 , 116, 2531-42	88
250	Gas-fragmentation study of the novel synthetic zwitterionic drug 3-methyl-9-(2-oxa-2lambda5-2H-1,3,2-oxazaphosphorine-2-cyclohexyl)-3,6,9-triazaspiro[5,5]undecane chloride (SLXM-2) by electrospray ionization tandem mass spectrometry. 2010 , 24, 1181-4	1
249	The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation. 2010 , 70, 844-53	38
248	Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. 2010 , 70, 1564-72	187
247	Proposal for dosage adjustment and timing of chemotherapy in hemodialyzed patients. 2010 , 21, 1395-1403	112
246	Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR. 2010 , 2, 1451-68	61
245	Cyclophosphamide and the Teratology Society: an awkward marriage. 2010 , 89, 289-99	13
244	Pharmacokinetics of anti-cancer drugs used in breast cancer chemotherapy. 2010 , 678, 124-32	14
243	Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy. 2011 , 47, 1556-63	15
242	Immunosuppressive effect of cyclophosphamide on white blood cells and lymphocyte subpopulations from peripheral blood of Balb/c mice. 2011 , 11, 1293-7	73
241	Cyclophosphamide-induced disruption of umami taste functions and taste epithelium. 2011 , 192, 732-45	27
240	[Treatment of rheumatic diseases: current status and future prospective. Topics: II. Immunosuppressant/antirheumatic drugs; 3. Cyclophosphamide for systemic rheumatic diseases]. 2011 , 100, 2918-23	
239	The chemotherapy metabolite acrolein upregulates thrombin generation and impairs the protein C anticoagulant pathway in animal-based and cell-based models. 2011 , 9, 767-75	14
238	Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011 , 68, 897-904	3-5 11

237	Association of cyclophosphamide use with dental developmental defects and salivary gland dysfunction in recipients of childhood antineoplastic therapy. 2011 , 117, 2219-27		25
236	Zebrafish (<i>Danio rerio</i>) embryos as a model for testing proteratogens. 2011 , 281, 25-36		141
235	Current and future treatment approaches for neuromyelitis optica. 2011 , 4, 111-21		64
234	Management of hematological malignancies in patients affected by renal failure. 2011 , 11, 415-32		7
233	Simultaneous determination of cyclophosphamide and 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry - application to Chinese systemic lupus erythematosus patients. 2011 , 49, 2029-37		7
232	Structure and function of cytochromes P450 2B: from mechanism-based inactivators to X-ray crystal structures and back. 2011 , 39, 1113-21		23
231	Anti-metabolic syndrome and immunostimulant activities of Egyptian fenugreek seeds in diabetic/obese and immunosuppressive rat models. 2011 , 105, 995-1004		17
230	Population pharmacokinetics of rituximab in patients with chronic lymphocytic leukemia. 2012 , 52, 1918-26		57
229	Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT. <i>Bone Marrow Transplantation</i> , 2012 , 47, 1178-85	4-4	13
228	[Management of chemotherapy in hemodialysis patients]. 2012 , 99, 371-80		5
227	Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo. 2012 , 40, 54-63		37
226	Purine analogues plus cyclophosphamide versus purine analogues alone for first-line therapy of patients with chronic lymphocytic leukaemia. 2012 ,		
225	Induction of cytochrome P450 enzymes: a view on human in vivo findings. 2012 , 5, 569-85		49
224	Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis. 2012 , 74, 445-55		35
223	Anticancer Drugs. 2012 , 365-378		
222	Aprepitant pharmacokinetics and assessing the impact of aprepitant on cyclophosphamide metabolism in cancer patients undergoing hematopoietic stem cell transplantation. 2012 , 52, 586-94		22
221	A phase II multicenter study of two different dosages of pemetrexed given in combination with cyclophosphamide as first-line treatment in patients with locally advanced or metastatic breast cancer. 2012 , 30, 309-16		7
220	Occupational exposure to antineoplastic drugs in four Italian health care settings. 2012 , 213, 107-15		55

219	Cytostatic drugs in infants: a review on pharmacokinetic data in infants. 2012 , 38, 3-26		19
218	Immunomodulatory Therapies. 2012 , 577-589		
217	Cutaneous and systemic pathogenicity of a clinical isolate of <i>Cladosporium sphaerospermum</i> in a murine model. 2012 , 147, 354-9		7
216	Phenotyping drug disposition in oncology. 2012 , 38, 715-25		8
215	Pharmacokinetic and pharmacogenetic determinants and considerations in chemotherapy selection and dosing in infants. 2012 , 8, 709-22		2
214	Genetic variations in multiple myeloma II: association with effect of treatment. 2012 , 88, 93-117		24
213	Patterns of chemotherapy-induced toxicities in younger children and adolescents with rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee. 2012 , 118, 1130-7		56
212	The cyclophosphamide metabolite, acrolein, induces cytoskeletal changes and oxidative stress in Sertoli cells. 2012 , 39, 493-500		46
211	Early-phase GVHD gene expression profile in target versus non-target tissues: kidney, a possible target?. <i>Bone Marrow Transplantation</i> , 2013 , 48, 284-93	4-4	18
210	Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation. 2013 , 69, 1543-51		14
209	Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case-control study of contralateral breast cancer risk in the WECARE Study. 2013 , 24, 1605-14		4
208	A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients. <i>Cancer Chemotherapy and Pharmacology</i> , 2013 , 72, 607-18	3-5	5
207	Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. 2013 , 5, 826-37		83
206	CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia. 2013 , 122, 4253-8		26
205	Hormone-related pharmacokinetic variations associated with anti-breast cancer drugs. 2013 , 9, 1085-95		1
204	Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. 2013 , 14, 75-87		36
203	Treatment of a frail older patient with diffuse large B-cell lymphoma on maintenance dialysis: attenuated immunochemotherapy and adapted care plan. 2013 , 6, 197-203		9
202	Involvement of interleukin-6-regulated nitric oxide synthase in hemorrhagic cystitis and impaired bladder contractions in young rats induced by acrolein, a urinary metabolite of cyclophosphamide. 2013 , 131, 302-10		20

201	The role of cyclophosphamide in enhancing antitumor efficacy of an adenovirus oncolytic vector in subcutaneous Syrian hamster tumors. 2013 , 20, 521-30		19
200	Immunomodulatory effects of polysaccharopeptide in immunosuppressed mice induced by cyclophosphamide. 2013 , 8, 669-75		11
199	Pre-treatment with amifostine protects against cyclophosphamide-induced disruption of taste in mice. <i>PLoS ONE</i> , 2013 , 8, e61607	3.7	21
198	Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: an exploratory study. 2014 , 10, 3394-408		12
197	Leukemia from dermal exposure to cyclophosphamide among nurses in The Netherlands: quantitative assessment of the risk. 2014 , 58, 271-82		14
196	Late-onset anaphylactic reactions following i.v. cyclophosphamide pulse in a patient with systemic sclerosis and systemic lupus erythematosus overlap syndrome. 2014 , 41, 912-4		2
195	Sphingosine-1-phosphate suppresses cyclophosphamide induced follicle apoptosis in human fetal ovarian xenografts in nude mice. 2014 , 102, 871-877.e3		35
194	Reconfigurable microfluidic hanging drop network for multi-tissue interaction and analysis. 2014 , 5, 4250		240
193	Islamic fasting and multiple sclerosis. 2014 , 14, 56		29
192	The association of cytochrome P450 genetic polymorphisms with sulfolane formation and the efficacy of a busulfan-based conditioning regimen in pediatric patients undergoing hematopoietic stem cell transplantation. 2014 , 14, 263-71		22
191	Pharmacokinetics and safety of cyclophosphamide and docetaxel in a hemodialysis patient with early stage breast cancer: a case report. 2015 , 15, 917		11
190	Ameliorative Effect of Gallic Acid on Cyclophosphamide-Induced Oxidative Injury and Hepatic Dysfunction in Rats. 2015 , 3, 78-92		19
189	Cyclophosphamide-Induced Morphological Changes in Dental Root Development of ICR Mice. <i>PLoS ONE</i> , 2015 , 10, e0133256	3.7	9
188	Secondary acute myeloid leukemia arising early after cyclophosphamide treatment. 2015 , 37, 289-91		4
187	Zn(II)-curcumin protects against oxidative stress, deleterious changes in sperm parameters and histological alterations in a male mouse model of cyclophosphamide-induced reproductive damage. 2015 , 39, 515-24		32
186	Therapeutic options for the treatment of non-infectious uveitis. 2015 , 10, 359-373		2
185	Antineoplastic drug contamination in the urine of Canadian healthcare workers. 2015 , 88, 933-41		48
184	Optimizing the use of existing therapies in lupus. 2015 , 18, 129-37		17

183	The GSTA1 polymorphism and cyclophosphamide therapy outcomes in lupus nephritis patients. 2015 , 160, 342-8		9
182	Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor. 2015 , 23, 1541-50		76
181	Improved immune responses to a bivalent vaccine of Newcastle disease and avian influenza in chickens by ginseng stem-leaf saponins. 2015 , 167, 147-55		33
180	Busulfan pretreatment for transplantation of rat spermatogonia differentially affects immune and reproductive systems in male recipient mice. 2015 , 90, 264-74		8
179	Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics. <i>Bone Marrow Transplantation</i> , 2015 , 50, 165-72	4.4	11
178	Cyclophosphamide inhibits root development of molar teeth in growing mice. 2015 , 103, 143-51		7
177	Purine analogues plus cyclophosphamide versus purine analogues alone for first-line therapy of patients with chronic lymphocytic leukaemia. 2016 ,		78
176	In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2016 , 11, e0166891	3.7	52
175	Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed. 2016 , 4, 377-82		32
174	Inventory of oral anticancer agents: Pharmaceutical formulation aspects with focus on the solid dispersion technique. 2016 , 50, 247-263		29
173	The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 661-71	3.5	167
172	Pharmacologic Treatment of Noninfectious Uveitis. 2017 , 242, 231-268		5
171	MicroRNA hsa-miR-25-3p suppresses the expression and drug induction of CYP2B6 in human hepatocytes. 2016 , 113, 88-96		38
170	Pharmacokinetics, Pharmacodynamics and Pharmacogenomics of Immunosuppressants in Allogeneic Haematopoietic Cell Transplantation: Part I. <i>Clinical Pharmacokinetics</i> , 2016 , 55, 525-50	6.2	20
169	Seizures and cancer: drug interactions of anticonvulsants with chemotherapeutic agents, tyrosine kinase inhibitors and glucocorticoids. 2016 , 3, 245-260		30
168	Cyclophosphamide in dermatology. 2017 , 58, 5-17		32
167	Efficacy, safety, and dose adjustment of cyclophosphamide in lymphoma patients requiring hemodialysis. 2017 , 58, 457-460		2
166	Enantioselectivity in the Metabolism of Cyclophosphamide in Patients With Multiple or Systemic Sclerosis. 2017 , 57, 784-795		2

165	Acrolein Can Cause Cardiovascular Disease: A Review. 2017 , 17, 227-236		64
164	The importance of drug metabolites synthesis: the case-study of cardiotoxic anticancer drugs. 2017 , 49, 158-196		17
163	Possible involvement of Nrf2 and PPAR α -regulation in the protective effect of umbelliferone against cyclophosphamide-induced hepatotoxicity. <i>Biomedicine and Pharmacotherapy</i> , 2017 , 86, 297-306	7.5	95
162	The protective effects of Cichorium glandulosum seed and cynarin against cyclophosphamide and its metabolite acrolein-induced hepatotoxicity in vivo and in vitro. 2017 , 8, 209-219		19
161	The multifactorial origin of posterior reversible encephalopathy syndrome in cyclophosphamide-treated lupus patients. 2017 , 37, 2105-2114		11
160	Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. 2017 , 13, 901-923		46
159	IL-1 Receptor-Knockout Mice Develop Epidermal Cysts and Show an Altered Innate Immune Response after Exposure to UVB Radiation. 2017 , 137, 2417-2426		12
158	Age-dependent Protein Abundance of Cytosolic Alcohol and Aldehyde Dehydrogenases in Human Liver. 2017 , 45, 1044-1048		23
157	Rare Cyclophosphamide-Induced Hemorrhagic Cystitis in a Chinese Population with Rheumatic Diseases. 2017 , 4, 175-182		3
156	Bioanalytical methods for cytostatic therapeutic drug monitoring and occupational exposure assessment. 2017 , 93, 152-170		11
155	Immunomodulatory, Immunoablative, and Biologic Therapies. 2017 , 567-582		1
154	Electrochemical sensing platform based on molecularly imprinted polymer decorated N,S co-doped activated graphene for ultrasensitive and selective determination of cyclophosphamide. 2017 , 164, 601-607		49
153	Immunosuppressive Drugs. 2017 , 983-998.e4		2
152	Time- and NADPH-Dependent Inhibition on CYP3A by Gomisin A and the Pharmacokinetic Interactions between Gomisin A and Cyclophosphamide in Rats. 2017 , 22,		7
151	A sensitive and rapid ultra high-performance liquid chromatography with tandem mass spectrometric assay for the simultaneous quantitation of cyclophosphamide and the 4-hydroxycyclophosphamide metabolite in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2018 , 1086, 56-62	3.2	6
150	Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis: A Systematic Review and Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 937-944	4.7	25
149	Analysis of the Effect of Cyclophosphamide and Methotrexate on <i>Chrysomya megacephala</i> (Diptera: Calliphoridae). 2018 , 63, 1413-1418		1
148	Breakthroughs in modern cancer therapy and elusive cardiotoxicity: Critical research-practice gaps, challenges, and insights. 2018 , 38, 325-376		29

147	Synthesis, quality control, and bio-evaluation of Tc-cyclophosphamide. 2018 , 91, 456-462		8
146	Schisandra chinensis extract decreases chloroacetaldehyde production in rats and attenuates cyclophosphamide toxicity in liver, kidney and brain. 2018 , 210, 223-231		26
145	Gosha-Jinki-Gan Recovers Spermatogenesis in Mice with Busulfan-Induced Aspermatogenesis. <i>International Journal of Molecular Sciences</i> , 2018 , 19,	6.3	10
144	Ameliorative effect of zinc oxide nanoparticles on cyclophosphamide induced testicular injury in adult rat. 2018 , 54, 80-93		16
143	Antiepileptic Drugs and Chemotherapy: Potential Interactions and Impact on Treatment of Patients With Cancer. 2018 , 45-58		
142	Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes. <i>Cancer Chemotherapy and Pharmacology</i> , 2019 , 84, 487-499 ^{3.5}		30
141	A high-specificity immunoassay for the therapeutic drug monitoring of cyclophosphamide. 2019 , 144, 5172-5178		6
140	Severe and prolonged cyclophosphamide-induced hepatotoxicity in a breast cancer patient carrying a variant. 2019 , 20, 1119-1124		6
139	Early Effects of Cyclophosphamide, Methotrexate, and 5-Fluorouracil on Neuronal Morphology and Hippocampal-Dependent Behavior in a Murine Model. 2020 , 173, 156-170		8
138	Mitochondrial and lysosomal protective agents ameliorate cytotoxicity and oxidative stress induced by cyclophosphamide and methotrexate in human blood lymphocytes. 2019 , 38, 1266-1274		11
137	The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes. 2019 , 85, 1925-1934		12
136	Effect of GSTP1 polymorphism on efficacy and safety of cyclophosphamide aggressive therapy in lupus nephropathy patients. 2019 , 35, 334-340		2
135	Microfluidic Multitissue Platform for Advanced Embryotoxicity Testing In Vitro. 2019 , 6, 1900294		29
134	The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells. 2019 , 9,		4
133	A. Berger Extracts Induce Immunity-Enhancing Effects on Cyclophosphamide-Treated Immunosuppressed Rats. <i>BioMed Research International</i> , 2019 , 2019, 9461960	3	5
132	Wuzhi capsule regulates chloroacetaldehyde pharmacokinetics behaviour and alleviates high-dose cyclophosphamide-induced nephrotoxicity and neurotoxicity in rats. 2019 , 125, 142-151		9
131	Effect of Chemotherapeutics and Tocopherols on MCF-7 Breast Adenocarcinoma and KGN Ovarian Carcinoma Cell Lines. <i>BioMed Research International</i> , 2019 , 2019, 6146972	3	8
130	Cyclophosphamide enhances the release of tumor exosomes that elicit a specific immune response in vivo in a murine T-cell lymphoma. 2019 , 37, 1565-1576		9

129	CNS Penetration of Cyclophosphamide and Metabolites in Mice Bearing Group 3 Medulloblastoma and Non-Tumor Bearing Mice. 2019 , 22, 612-629		3
128	Other Forms of Immunosuppression. 2019 , 313-332		
127	Fractionated head and neck irradiation impacts taste progenitors, differentiated taste cells, and Wnt/ β -catenin signaling in adult mice. <i>Scientific Reports</i> , 2019 , 9, 17934	4.9	13
126	Kinetics of Cyclophosphamide Metabolism in Humans, Dogs, Cats, and Mice and Relationship to Cytotoxic Activity and Pharmacokinetics. 2019 , 47, 257-268		13
125	Cyclophosphamide Use in Multiple Sclerosis: Levels Detected in Human Milk. 2019 , 14, 128-130		3
124	Pharmacology of new and developing intravenous therapies for the management of seizures and epilepsy. 2019 , 20, 25-39		3
123	Whole-body Imaging of Cell Death Provides a Systemic, Minimally Invasive, Dynamic, and Near-real Time Indicator for Chemotherapeutic Drug Toxicity. 2019 , 25, 1331-1342		6
122	Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options. 2019 , 79, 125-142		36
121	Pavlovian Conditioning of Immunological and Neuroendocrine Functions. 2020 , 100, 357-405		20
120	Neuro-Behcet's disease: An update on diagnosis, differential diagnoses, and treatment. 2019 , 39, 101906		22
119	Cyclophosphamide has Long-Term Effects on Proliferation in Olfactory Epithelia. 2020 , 45, 97-109		3
118	The effects of magnesium sulfate on cyclophosphamide-induced ovarian damage: Folliculogenesis. 2020 , 122, 151470		2
117	Quantification of 3-Hydroxypropyl Mercapturic Acid in the Urine of Patients with Breast Cancer to Monitor Cyclophosphamide Toxicity. 2020 , 42, 548-553		4
116	Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance. 2020 , 11, 1376		6
115	Hypersensitivity of bladder low threshold, wide dynamic range, afferent fibres following treatment with the chemotherapeutic drugs cyclophosphamide and ifosfamide. <i>Archives of Toxicology</i> , 2020 , 94, 2785-2797	5.8	5
114	Immunosuppressive and immunomodulator therapy for rare or uncommon skin disorders in pandemic days. 2020 , 33, e13686		6
113	ACROLEIN AND UNSATURATED ALDEHYDES. 2020 , 205-259		2
112	Transient Effects of Cyclophosphamide on Basal Cell Proliferation of Olfactory Epithelia. 2020 , 45, 549-561		0

111 Cytochrome P450 Inhibition. **2020**, 183-261

110 Exposure-Toxicity Association of Cyclophosphamide and Its Metabolites in Infants and Young Children with Primary Brain Tumors: Implications for Dosing. **2020**, 26, 1563-1573 6

109 Treatment of systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials.. *Journal of Scleroderma and Related Disorders*, **2020**, 5, 61-71 2.3 26

108 The Traditional Chinese Medicine Fufang Shatai Heji (STHJ) Enhances Immune Function in Cyclophosphamide-Treated Mice. **2020**, 2020, 3849847 4

107 Anti-neoplastic agents for patients on peritoneal dialysis: A systematic review. **2020**, 150, 102947 3

106 Ocular side effects of antirheumatic medications: a qualitative review. **2020**, 5, e000331 7

105 Genetic Polymorphism of GSTP-1 Affects Cyclophosphamide Treatment of Autoimmune Diseases. **2020**, 25, 4

104 Population Pharmacokinetic, Pharmacogenetic, and Pharmacodynamic Analysis of Cyclophosphamide in Ethiopian Breast Cancer Patients. *Frontiers in Pharmacology*, **2020**, 11, 406 5.6 3

103 Lower proximal cup and outer root sheath cells regenerate hair bulbs during anagen hair follicle repair after chemotherapeutic injury. **2021**, 30, 503-511 1

102 Cytotoxic Agents. **2021**, 209-221.e5

101 Influence of glutathione S transferase A1 gene polymorphism (-69C > T, rs3957356) on intravenous cyclophosphamide efficacy and side effects: a case-control study in Egyptian patients with lupus nephritis. **2021**, 40, 753-762 4

100 Engineered Microsystems for Spheroid and Organoid Studies. **2021**, 10, e2001284 18

99 Degradation of cyclophosphamide during UV/chlorine reaction: Kinetics, byproducts, and their toxicity. **2021**, 268, 128817 10

98 Structural characterization and effect on leukopenia of fucoidan from *Durvillaea antarctica*. **2021**, 256, 117529 5

97 Drug repurposing for breast cancer therapy: Old weapon for new battle. **2021**, 68, 8-20 33

96 Graft-Versus-Host Disease (GvHD) Prophylaxis. **2021**, 153-186

95 Phenotyping Study of Cyclophosphamide 4-Hydroxylation in Malay Cancer Patients. **2021**, 15, 305-313 3

94 Cyclophosphamide-Induced Inflammation of Taste Buds and Cytoprotection by Amifostine. **2021**, 46, 1

93	Cyclophosphamide exposure assessed with the biomarker phosphoramidate mustard-hemoglobin in breast cancer patients: The TailorDose I study. <i>Scientific Reports</i> , 2021 , 11, 2707	4.9	1
92	Impaired Kidney Function Associated with Increased Risk of Side Effects in Patients with Small Vessel Vasculitis Treated with Rituximab as an Induction Therapy. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	0
91	Metabolic regulation mechanism of fucoidan via intestinal microecology in diseases. <i>Journal of the Science of Food and Agriculture</i> , 2021 , 101, 4456-4463	4.3	4
90	Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	3
89	Effects of Green cardamom (<i>Elettaria cardamomum</i> Maton) and its combination with cyclophosphamide on Ehrlich solid tumors. <i>BMC Complementary Medicine and Therapies</i> , 2021 , 21, 133	2.9	2
88	Principles of Drug Metabolism. 1-139		
87	Cyclophosphamide-associated enteritis presenting with severe protein-losing enteropathy in granulomatosis with polyangiitis: A case report. <i>World Journal of Gastroenterology</i> , 2021 , 27, 2657-2663	5.6	1
86	Experimental Assessment of Possible Factors Associated with Tick-Borne Encephalitis Vaccine Failure. <i>Microorganisms</i> , 2021 , 9,	4.9	2
85	Anti-inflammatory effects of thymoquinone and its protective effects against several diseases. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 138, 111492	7.5	10
84	Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2464-2470	4.4	0
83	Chemotherapy for non-Hodgkin lymphoma in the hemodialysis patient: A comprehensive review. <i>Cancer Science</i> , 2021 , 112, 2607-2624	6.9	4
82	Cyclophosphamide bioactivation pharmacogenetics in breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 88, 533-542	3.5	3
81	Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust. <i>HemaSphere</i> , 2021 , 5, e580	0.3	2
80	CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations-Implication for Drug Safety, Dosing, and Individualized Therapy. <i>Frontiers in Genetics</i> , 2021 , 12, 692234	4.5	4
79	Pharmacogenomic associations of cyclophosphamide pharmacokinetic candidate genes with event-free survival in intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2021 , 68, e29203	3	0
78	Digestive properties and effects of Chimonanthus nitens Oliv polysaccharides on antioxidant effects in vitro and in immunocompromised mice. <i>International Journal of Biological Macromolecules</i> , 2021 , 185, 306-316	7.9	3
77	Higher Fludarabine and Cyclophosphamide Exposures Lead to Worse Outcomes in Reduced-Intensity Conditioning Hematopoietic Cell Transplantation for Adult Hematologic Malignancy. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 773.e1-773.e8		0
76	Ontogeny of Drug-Metabolizing Enzymes. <i>Methods in Molecular Biology</i> , 2021 , 2342, 551-593	1.4	0

75	The Role of Alcohol Dehydrogenase in Drug Metabolism: Beyond Ethanol Oxidation. <i>AAPS Journal</i> , 2021 , 23, 20	3.7	8
74	Immunosuppressive Drugs. 2013 , 941-956.e4		2
73	Hemorrhagic Cystitis after Haploidentical Transplantation with Post-Transplantation Cyclophosphamide: Protective Effect of MESNA Continuous Infusion. <i>Biology of Blood and Marrow Transplantation</i> , 2020 , 26, 1492-1496	4.7	5
72	Delicate balances in cancer chemotherapy: Modeling immune recruitment and emergence of systemic drug resistance.		1
71	A curative combination therapy for lymphomas achieves high fractional cell killing through low cross-resistance and drug additivity but not synergy.		2
70	Synthesis of cyclophosphamide metabolites by a peroxygenase from <i>Marasmius rotula</i> for toxicological studies on human cancer cells. <i>AMB Express</i> , 2020 , 10, 128	4.1	4
69	Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide. <i>PLoS ONE</i> , 2016 , 11, e0151696	3.7	11
68	Drugs in a Curative Combination Therapy for Lymphoma Exhibit Low Cross-Resistance But Not Pharmacological Synergy. <i>SSRN Electronic Journal</i> ,	1	3
67	Arzneimitteltherapiesicherheit: Das Interaktionspotenzial konventioneller Zytostatika.		2
66	Establishment of a Mouse Thrombocytopenia Model Induced by Cyclophosphamide. <i>Zoological Research</i> , 2010 , 30, 645-652		4
65	A curative combination cancer therapy achieves high fractional cell killing through low cross-resistance and drug additivity. <i>ELife</i> , 2019 , 8,	8.9	27
64	He-Wei Granule enhances anti-tumor activity of cyclophosphamide by changing tumor microenvironment. <i>Chinese Herbal Medicines</i> , 2021 , 14, 79-79	1.4	0
63	Laminaria japonica fucoidan ameliorates cyclophosphamide-induced liver and kidney injury possibly by regulating Nrf2/HO-1 and TLR4/NF- κ B signaling pathways. <i>Journal of the Science of Food and Agriculture</i> , 2021 ,	4.3	1
62	Severe Leukopenia after Intravenous Cyclophosphamide Pulse Therapy in a Patient Having Cytochrome P450 2A6*1B. <i>The Journal of the Korean Rheumatism Association</i> , 2007 , 14, 144		
61	Other Forms of Immunosuppression. 2008 , 333-349		2
60	SYSTEMIC LUPUS ERYTHEMATOSUS. 2009 , 1047-1062		
59	Immunoregulatory Drugs. 2009 , 909-927		1
58	TRANSPLANT MEDICINE. 2009 , 1269-1294		

57	Other Forms of Immunosuppression. 2014 , 320-338		0
56	Immunosuppressives. 2015 , 459-467		1
55	Cyclophosphamide Promotes Arrested Development of the Dental Root in Mice. <i>Journal of Hard Tissue Biology</i> , 2020 , 29, 63-70	0.4	1
54	Immunomodulatory Potential of the Industrialized Fermentation Product In Vitro and in Wistar Rats. <i>Foods</i> , 2021 , 10,	4.9	3
53	Paradoxical manifestations during tuberculous meningitis treatment among HIV-negative patients: a retrospective descriptive study and literature review. <i>Neurological Sciences</i> , 2021 , 1	3.5	0
52	Four decades of chemotherapy-induced cognitive dysfunction: comprehensive review of clinical, animal and in vitro studies, and insights of key initiating events. <i>Archives of Toxicology</i> , 2021 , 1	5.8	2
51	Efficacy of two cyclophosphamide regimens for the treatment of lupus nephritis in Puerto Ricans: low vs. standard dose. <i>Ethnicity and Disease</i> , 2010 , 20, S1-116-21	1.8	1
50	Treatment of systemic sclerosis associated ILD: Lessons from clinical trials. <i>Journal of Scleroderma and Related Disorders</i> , 2020 , 5, 61-71	2.3	12
49	Relevant pharmacological interactions between alkylating agents and antiepileptic drugs: Preclinical and clinical data. <i>Pharmacological Research</i> , 2021 , 175, 105976	10.2	0
48	Drug Metabolism: Other Phase I Enzymes. 2021 ,		
47	Effects of cyclophosphamide related genetic variants on clinical outcomes of adult hematopoietic cell transplant patients.. <i>Cancer Chemotherapy and Pharmacology</i> , 2022 , 89, 543	3.5	0
46	Association between the magnitude of intravenous busulfan exposure and development of hepatic veno-occlusive disease in children and young adults undergoing myeloablative allogeneic hematopoietic cell transplantation.. <i>Transplantation and Cellular Therapy</i> , 2022 ,		0
45	Cardiotoxicity of cyclophosphamide's metabolites: an in vitro metabolomics approach in AC16 human cardiomyocytes.. <i>Archives of Toxicology</i> , 2022 , 96, 653	5.8	0
44	Duration of sweat cyclophosphamide excretion in patients undergoing a conditioning regimen of high-dose cyclophosphamide for hematopoietic stem-cell transplantation.. <i>Journal of Oncology Pharmacy Practice</i> , 2022 , 10781552221077035	1.7	1
43	Lung Regeneration by Transplantation of Allogeneic Lung Progenitors Using a Safer Conditioning Regimen and Clinical-grade Reagents.. <i>Stem Cells Translational Medicine</i> , 2022 , 11, 178-188	6.9	
42	Modelling myeloablative cytostatic therapy with cyclophosphamide is accompanied by gastrointestinal stasis in rats. 2022 ,		0
41	Pharmacometabonomic Association of Cyclophosphamide 4-hydroxylation in Hematopoietic Cell Transplant Recipients.. <i>Clinical and Translational Science</i> , 2022 ,	4.9	0
40	An ex vivo organ culture screening model revealed that low temperature conditions prevent side effects of anticancer drugs.. <i>Scientific Reports</i> , 2022 , 12, 3093	4.9	0

39	The Effects of Immunosuppression on the Lung Microbiome and Metabolites in Rats.. <i>Frontiers in Microbiology</i> , 2022 , 13, 817159	5.7	0
38	Use of EuroLupus Cyclophosphamide Dosing for the Treatment of Lupus Nephritis in Childhood-onset Systemic Lupus Erythematosus in North America.. <i>Journal of Rheumatology</i> , 2022 ,	4.1	0
37	Current Treatment of Myasthenia Gravis.. <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	1
36	Cyclophosphamide, hydroxycyclophosphamide and carboxyethyl phosphoramidate mustard quantification with liquid chromatography mass spectrometry in a single run human plasma samples: A rapid and sensitive method development.. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2022 , 1200, 120000	3.2	0
35	Analysis of the mechanism underlying the effects of cyclophosphamide against triple-negative breast cancer by an integrative bioinformatics approach. <i>International Journal of Pharmaceutical Sciences and Developmental Research</i> , 006-015	0.3	
34	An Explainable Supervised Machine Learning Model for Predicting Respiratory Toxicity of Chemicals Using Optimal Molecular Descriptors.. <i>Pharmaceutics</i> , 2022 , 14,	6.4	2
33	Potential Protective Effects of Antioxidants against Cyclophosphamide-Induced Nephrotoxicity.. <i>International Journal of Nephrology</i> , 2022 , 2022, 5096825	1.7	2
32	Drug Repurposing in Cancer Therapy: Influence of Patient's Genetic Background in Breast Cancer Treatment.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	2
31	Boswellic Acids, Pentacyclic Triterpenes, Attenuate Oxidative Stress, and Bladder Tissue Damage in Cyclophosphamide-Induced Cystitis.. <i>ACS Omega</i> , 2022 , 7, 13697-13703	3.9	1
30	Abatement of cyclophosphamide-induced splenic immunosuppressive indoleamine 2, 3-dioxygenase and altered hematological indices in Wister rats by dietary quercetin.. <i>Immunobiology</i> , 2022 , 227, 152218	3.4	0
29	Data_Sheet_1.PDF. 2020 ,		
28	A parallelized, perfused 3D triculture model of leukemia for in vitro drug testing of chemotherapeutics.. <i>Biofabrication</i> , 2022 ,	10.5	0
27	MPOANCA-Positive Granulomatosis with Polyangiitis with Rapidly Progressive Glomerulonephritis and Saddle-Nose Deformity: A Case Report. <i>Antibodies</i> , 2022 , 11, 33	7	0
26	Cytotoxic agents. 2013 , 212-227.e4		4
25	Revisited Cyclophosphamide in the Treatment of Lupus Nephritis. <i>BioMed Research International</i> , 2022 , 2022, 1-9	3	
24	Microfluidic Chip as a Tool for Effective In Vitro Evaluation of Cyclophosphamide Prodrug Toxicity. <i>Bulletin of Experimental Biology and Medicine</i> , 2022 , 173, 146-150	0.8	
23	Quantification of N, NINEtriethylenethiophosphoramidate, N, NINEtriethylenephosphoramidate, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies.. <i>Journal of Chromatography Open</i> , 2022 , 100054		
22	Quantification of three antineoplastic agents in urine using the UniSpray ionisation source. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2022 , 1205, 123331	3.2	

21	Cancer Drug Dosing in Chronic Kidney Disease and Dialysis. <i>Advances in Chronic Kidney Disease</i> , 2022 , 29, 208-216.e1	4.7	
20	Hodgkin lymphoma on hemodialysis: a review of treatment and recommendations. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022 ,	2	
19	Individualized medication based on pharmacogenomics and treatment progress in children with IgAV nephritis. <i>Frontiers in Pharmacology</i> , 13,	5.6	○
18	Cyclophosphamide for Treatment of Refractory Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Systematic Review and Meta-analysis. <i>Clinical Therapeutics</i> , 2022 ,	3.5	
17	Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy. 2022 , 8,		○
16	Outcomes of CD19 targeted CAR T-cell Therapy for Patients with Reduced Renal Function Including Dialysis. 2022 ,		○
15	Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis. 2022 ,		○
14	Lipidomics of cyclophosphamide 4-hydroxylation in patients receiving post-transplant cyclophosphamide.		○
13	Influence of Renal Function on Phosphoramidate Mustard Exposure: A Nonlinear Mixed-Effects Analysis.		○
12	Quercetin alleviates cyclophosphamide-induced premature ovarian insufficiency in mice by reducing mitochondrial oxidative stress and pyroptosis in granulosa cells.		○
11	Lymphodepleting chemotherapy practices and effect on safety and efficacy outcomes in patients with solid tumours undergoing T cell receptor-engineered T cell (TCR-T) Therapy: a systematic review and meta-analysis.		○
10	Biological Monitoring via Urine Samples to Assess Healthcare Workers' Exposure to Hazardous Drugs: A Scoping Review. 2022 , 12, 11170		○
9	Quercetin alleviates cyclophosphamide-induced premature ovarian insufficiency in mice by reducing mitochondrial oxidative stress and pyroptosis in granulosa cells. 2022 , 15,		○
8	Mafosfamide, a cyclophosphamide analog, causes a proinflammatory response and increased permeability on endothelial cells in vitro.		○
7	Protective effects of hesperidin in cyclophosphamide-induced parotid toxicity in rats. 2023 , 13,		○
6	Altered hallmarks of DNA double-strand breaks, oxidative DNA damage and cytogenotoxicity by piperlongumine in hippocampus and hepatocytes of rats intoxicated with cyclophosphamide. 2023 , 121391		○
5	Immunomodulatory effects and mechanisms of Tiejishihu Xiyangshen granules on cyclophosphamide induced immuno-suppression via TLR4/MAPKs and PI3K/AKT/FOXO3a signal pathways. 2023 , 307, 116192		○
4	Prediction of Nonrelapse Mortality in Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia Receiving Allogeneic Stem Cell Transplantation With Posttransplantation Cyclophosphamide-based Graft Versus Host Disease Prophylaxis. 2023 , 7, e846		○

- 3 Overcoming chemoresistance in non-angiogenic colorectal cancer by metformin via inhibiting endothelial apoptosis and vascular immaturity. **2023**, 13, 262-275 ○
- 2 Recent advances in the treatment of systemic sclerosis associated interstitial lung disease. 10, ○
- 1 Precision Oncology by Point-of-Care Therapeutic Drug Monitoring and Dosage Adjustment of Conventional Cytotoxic Chemotherapies: A Perspective. **2023**, 15, 1283 ○